Table 1.
Brief summary of studies with main TIPS-related complications in patients with HCC.
| Study | Study Type | Number of Subjects | Child–Pugh Score | Median Follow-Up | Technical Success | Liver Failure | Tumor Rupture | Stent Disfunction | Dissemination |
|---|---|---|---|---|---|---|---|---|---|
| Qiu B et al., 2015 [14] | Retrospective | 209 | A 83 (39.7%) B 72 (34.4%) C 54 (25.8%) |
Until death or 5 years | 209 (100%) | 0 (0%) | N/A | 122 (58.4%) | 0 (0%) |
| Liu L et al., 2013 [15] | Retrospective | 58 | A 11 (19%) B 34 (58.6%) C 13 (22.4%) |
78.5 days | 58 (100%) | 0 (0%) | 5 (8.6%) | 12 (20.7%) | 7 (12%, lung and abdominal lymph nodes metastasis) |
| Tsauo J et al., 2021 [16] | Retrospective | 126 | N/A | 13.9 months | 124 (94.4%) | 1 (0.79%) | 1 (0.79%) | 15 (11.9% mean follow up time of 11.4 months) | 3 (2.4% lung metastasis) |
| Bettinger, et al., 2015 [19] | Retrospective | 40 | A 3 (7.5%) B 29 (72.5%) C 8 (20%) |
211 days | 40 (100%) | 2 (5%) | 0 (0%) | 8 (20%) | 1 (2.5%) |
| Jiang et al., 2004 [20] | Retrospective | 14 | A 0 (0%) B 4 (28.6%) C 10 (71.4%) |
90 days | 10 (71.4%) | N/A | N/A | N/A | 0 (0%, 3 months follow up) |
| Wallace et al., 2003 [9] | Retrospective | 9 (all TIPS trough HCC) | N/A | 229 days | 9 (100%) | 1 (11%) | N/A | 3 (33.3%) | 2 (22%, lung metastasis) |